PolyPid (PYPD)

Currency in USD
4.1800
-0.0900(-2.11%)
Closed·
4.19000.0000(0.00%)
·
PYPD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.15004.3789
52 wk Range
2.30005.1200
Key Statistics
Prev. Close
4.27
Open
4.225
Day's Range
4.15-4.3789
52 wk Range
2.3-5.12
Volume
54.44K
Average Volume (3m)
76.13K
1-Year Change
39.7993%
Book Value / Share
0.66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PYPD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.2500
Upside
+193.06%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

PolyPid News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Employees
59

PolyPid Earnings Call Summary for Q4/2025

  • PolyPid reported Q4 2025 loss of $0.41 per share, missing forecasts by 24.24%, with net loss of $8.5 million despite modest 2.18% stock increase to $4.68
  • Full-year R&D expenses increased to $23.8 million from $22.8 million in 2024, with cash position at $12.9 million as of December 31, 2025
  • Company completed SHIELD II Phase 3 trial and plans to submit New Drug Application by end of Q1 2026, anticipating expedited six-month FDA review
  • CEO Dikla Czaczkes Akselbrad projects 2026 as 'transformative year' with focus on strategic U.S. partnerships to expand market presence
  • Despite financial challenges, management emphasized Kynatrix technology platform's potential to enhance controlled release capabilities and drive future growth
Last Updated: 02/11/2026, 10:28 PM
Read Full Transcript

Compare PYPD to Peers and Sector

Metrics to compare
PYPD
Peers
Sector
Relationship
P/E Ratio
−2.2x−1.4x−0.5x
PEG Ratio
−0.04−0.010.00
Price/Book
6.9x0.8x2.6x
Price / LTM Sales
-1.0x3.3x
Upside (Analyst Target)
211.0%995.2%45.2%
Fair Value Upside
Unlock18.1%5.3%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.2500
(+193.06% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy14.00+234.93%-MaintainDec 01, 2025
Craig-Hallum
Buy13.00+211.00%15.00MaintainAug 14, 2025
Citizens JMP
Buy14.00+234.93%16.00MaintainJun 17, 2025
H.C. Wainwright
Buy13.00+211.00%11.00MaintainJun 10, 2025
Roth/MKM
Buy9.00+115.31%-New CoverageJun 05, 2025

Earnings

Latest Release
Feb 11, 2026
EPS / Forecast
-0.41 / -0.33
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PYPD Income Statement

People Also Watch

10.030
ONDS
-11.94%
3.560
SATL
+9.20%
2.0700
SIDU
-9.61%
13.970
VTYX
+0.07%

FAQ

What Is the PolyPid (PYPD) Stock Price Today?

The PolyPid stock price today is 4.1800

What Stock Exchange Does PolyPid Trade On?

PolyPid is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for PolyPid?

The stock symbol for PolyPid is "PYPD."

What Is the PolyPid Market Cap?

As of today, PolyPid market cap is 76.0900M.

What Is PolyPid's Earnings Per Share (TTM)?

The PolyPid EPS (TTM) is -2.0900.

When Is the Next PolyPid Earnings Date?

PolyPid will release its next earnings report on May 13, 2026.

From a Technical Analysis Perspective, Is PYPD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has PolyPid Stock Split?

PolyPid has split 1 times.

How Many Employees Does PolyPid Have?

PolyPid has 59 employees.

What is the current trading status of PolyPid (PYPD)?

As of Feb 21, 2026, PolyPid (PYPD) is trading at a price of 4.1800, with a previous close of 4.2700. The stock has fluctuated within a day range of 4.1500 to 4.3789, while its 52-week range spans from 2.3000 to 5.1200.

What Is PolyPid (PYPD) Price Target According to Analysts?

The average 12-month price target for PolyPid is USD12.2500, with a high estimate of USD14 and a low estimate of USD9. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +193.06% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.